Introduction {#sec1_1}
============

Coronary artery bypass graft surgery remains an important procedure despite improvements in percutaneous transluminal coronary interventions, especially for three-vessel and left main coronary artery disease \[[@B1]\]. The saphenous vein is the most widely used conduit \[[@B1]\]; however, only 50% of all vein grafts are patent without significant restenosis after 10 years and most failures occur 1--18 months after implantation \[[@B2],[@B3],[@B4]\]. Intermediate to late vein graft failure is caused by intimal hyperplasia with superimposed atherosclerosis \[[@B5]\]. Despite surgical and medical advances, saphenous vein graft (SVG) disease remains a significant problem that is associated with high morbidity and mortality rates \[[@B3]\]. Apart from statins, no drug has yet been proven to be clinically effective in preventing late vein graft failure \[[@B5]\]. Hence, an understanding of the pathophysiological mechanism of SVG disease is essential for preventing its formation and progression.

Erythropoietin (EPO) is a glycosylated protein hormone produced by renal peritubular fibroblasts in response to tissue hypoxia \[[@B6],[@B7]\]. EPO was once thought to act only on erythroid progenitor cells and was used to treat anemia in patients with renal disease; however, EPO messenger ribonucleic acid expression and EPO receptor have been observed in various types of tissues, including the brain, bone marrow, reproductive system, and heart \[[@B8],[@B9]\]. The EPO had been shown to act as a direct antioxidant by scavenging oxyradicals and is thought to have an antiatherogenic effect by down-regulating production of proinflammatory cytokine-induced endothelin-1 \[[@B10],[@B11]\]. The role of EPO in the atherosclerotic process remains to be fully elucidated.

To date, no study has investigated the relationship between the serum EPO level and SVG disease. Therefore, the aim of the present study was to determine the level of EPO in patients with and without SVGs in order to decipher the role of EPO in SVG disease.

Subjects and Methods {#sec1_2}
====================

The study population included 85 consecutive patients that had undergone coronary artery bypass graft surgery ≥12 months ago and then underwent elective coronary angiography for stable angina pectoris despite optimal medical treatment and had signs of ischemia based on noninvasive cardiac imaging tests. Exclusion criteria were any malignancy, renal failure (estimated glomerular filtration rate \<40 ml min^−1^) and hepatic failure, anemia, rheumatoid arthritis, sickle cell anemia, acquired immune deficiency syndrome, pulmonary hypertension, chronic obstructive lung disease, acute coronary syndrome during the previous month, severe valvular heart disease, and living at high altitudes. Written informed consent was obtained from each patient and the Institutional Ethics Committee approved the study protocol.

Coronary angiography was performed using standard angiographic techniques. All cineangiograms were reviewed by 2 interventional cardiologists who were blinded to the study protocol. Bypass grafts were examined in multiple projections and the degree of stenosis was determined based on the projection that showed the most severe narrowing. The stumps of occluded (100% stenosis) grafts were selectively injected or visualized via aortography in the appropriate projection. Any degree of stenosis of an SVG \>30% (moderate stenosis) was accepted as diseased. Patients with \>30% stenosis (diseased grafts) in at least one saphenous graft were included in group 1 (diseased group, n = 40), and group 2 (nondiseased group, n = 45) consisted of patients without diseased saphenous grafts.

Venous blood samples were drawn into a tube without anticoagulant following fasting of ≥8 h on the same day as coronary angiography; all the patients rested in the supine position for ≤1 h at the same time of day (13.00--14.00 h) to avoid diurnal variation. The EPO level was measured using enzyme-linked immunosorbent assay (ELISA) using a commercial ELISA kit (Biomerica, USA).

Statistical Analysis {#sec2_1}
--------------------

Data were analyzed using SPSS v.15.0 for Windows (SPSS Inc., Chicago, Ill., USA). Continuous variables are presented as mean ± SD, and categorical variables as frequency and percentage. Student\'s t test was used to compare normally distributed continuous variables and the Mann-Whitney U test was used for variables not normally distributed. Categorical variables were compared using the χ^2^ test. A two-tailed p value \<0.05 was considered statistically significant. Multivariate logistic regression analysis was performed to evaluate the independent associations with SVG disease. Parameters with a p value \<0.10 based on univariate analysis were included in the model. The odds ratio (OR) and 95% confidence interval (CI) were calculated.

Results {#sec1_3}
=======

The demographic and clinical characteristics of both groups are presented in table [1](#T1){ref-type="table"}. There were not any significant differences in age, gender, body mass index, and baseline medications between the groups. Laboratory parameters of both groups are summarized in table [2](#T2){ref-type="table"}. There were not any significant differences between the two groups, except for the lower serum high-density lipoprotein (HDL) cholesterol level (38.1 ± 8.2 vs. 43.8 ± 10.2 mg dl^−1^, p = 0.015) and higher triglyceride level (173.8 ± 88.5 vs. 131 ± 63.4 mg dl^−1^, p = 0.016) in groups 1 and 2, respectively. The mean EPO level in group 2 (25.5 ± 9.6 mU ml^−1^) was significantly higher than in group 1 (17.8 ± 6.8 mU ml^−1^, p = 0.002; fig. [1](#F1){ref-type="fig"}).

The multivariate logistic regression analysis showed that low serum EPO level was an independent predictor of SVG disease (OR 1.14, 95% CI 1.06--1.24, p = 0.001), also low HDL level was an independent predictor of SVG disease (OR 1.08, 95% CI 1.01--1.15, p = 0.017), but TG levels did not differ significantly between groups (OR 0.99, 95% CI 0.99--1.01, p = 0.42).

Discussion {#sec1_4}
==========

In the present study, the serum EPO levels were significantly lower in patients with than without diseased SVGs. This association remained significant after multivariate analysis, thereby indicating decreased serum EPO levels as an independent predictor of SVG disease. Hence, there were two independent predictors of SVG disease: low plasma EPO and low HDL levels. Failure to find a significant association between the classical risk factors of atherosclerosis, hypertension, diabetes mellitus, dyslipidemia and smoking except low HDL and SVG disease confirmed the finding of a previous study \[[@B12]\]. Additionally, the association between the serum EPO level and SVG disease persisted following logistic regression analysis.

A probable explanation of the role of serum EPO in SVG disease could be that it had been shown to have tissue-protecting effects, including suppression of atherosclerosis \[[@B13]\]. Earlier studies reported that administration of EPO decreased the cholesterol ester content in the aorta in animal models \[[@B14]\]. EPO was also shown to decrease intima-media thickness in hemodialyzed patients \[[@B15]\] and to suppress foam cell formation in murine macrophages \[[@B16]\]. Development of vascular endothelial injury while harvesting SVGs was shown to affect SVG patency \[[@B17]\]. EPO promotes reendothelialization and inhibits neointimal formation following vascular injury \[[@B18]\]. The antioxidant effect of EPO was also demonstrated in animal studies \[[@B19]\]. The present findings show that SVG disease was associated with a low serum EPO level, indicating that a low EPO level might be predictive of atherosclerosis and might contribute to atherosclerosis in patients with SVG disease.

Studies on recombinant human EPO showed that it had beneficial effects in heart failure models via stimulating angiogenesis and neovascularization \[[@B20],[@B21],[@B22]\]. Animal studies also suggested that there is a potential therapeutic role for recombinant human EPO in the treatment of myocardial ischemia and infarction, as it prevents apoptosis and reduces left ventricular functional decline. Based on the present study\'s findings, additional research on the role of EPO in SVG disease and its treatment is warranted.

The present study had some limitations. The direct role of EPO in SVG disease was not examined because of the study\'s observational and cross-sectional design. In addition, the study sample was small, which limits the value of the findings.

Conclusion {#sec1_5}
==========

A low EPO level was associated with SVG disease, suggesting that a low EPO level might play a pathophysiological role in the development of atherosclerotic lesions in SVGs. Hence, the use of EPO analogues might constitute a novel therapeutic strategy for suppressing atherosclerotic progression in SVGs.

Disclosure Statement {#sec1_6}
====================
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###### 

Baseline characteristics of the patients with SVGs

                         Diseased (n = 40)   Nondiseased (n = 45)   p value
  ---------------------- ------------------- ---------------------- ---------
  Age, years             63 ± 9.2 (42--82)   64 ± 9.3 (46--83)      NS
  SVG age, years         7.7 ± 4.9 (1--18)   6.7 ± 4.2 (1--18)      NS
  Hypertension           29 (64.5)           27 (67.5)              NS
  Diabetes mellitus      25 (62.5)           29 (64.5)              NS
  Acetylsalicylic acid   36 (90.0)           45 (100)               NS
  Statin                 27 (67.5)           28 (62.2)              NS
  Chronic lung disease   6 (15.o)            6 (13.3)               NS

Values are means ± SD (range) or n (%). NS = Nonsignificant (p \> 0.10).

###### 

Echocardiographic and blood test results in patients with SVGs

                                 Diseased (n = 40)          Nondiseased (n = 45)       p value
  ------------------------------ -------------------------- -------------------------- ---------
  Creatinine, mg dl^−1^          0.98 ± 0.16 (0.7--1.5)     0.93 ± 0.23 (0.58--1.62)   NS
  Urate, mg dl^−1^               5.4 ± 1.67 (2.4--9.9)      5.2 ± 1.32 (3.1--9.4)      NS
  Total cholesterol, mg dl^−1^   168.8 ± 38.1 (97--258)     165.9 ± 47.2 (85--320)     NS
  HDL cholesterol, mg dl^−1^     38.1 ± 8.2 (12--54)        43.8 ± 10.2 (26--70)       0.015
  LDL cholesterol, mg dl^−1^     95.8 ± 30.3 (47--176)      96.1 ± 39.5 (29--232)      NS
  Triglyceride, mg dl^−1^        173.8 ± 88.5 (68--490)     131 ± 63.4 (51--320)       0.016
  Hemoglobin, g dl^−1^           14.6 ± 1.14 (36.2--50)     14.3 ± 1.11 (12.0--16.9)   NS
  Hematocrit, %                  43.4 ± 3.57 (26.4--35.1)   42.6 ± 3.42 (35.4--50.9)   NS
  Sedimentation rate, mm h^−1^   12.2 ± 6.6 (3--32)         10.7 ± 4.7 (2--21)         NS
  Fibrinogen, g l^−1^            3.03 ± 0.51 (2.0--4.3)     3.12 ± 0.61 (2.1--4.4)     NS
  EPO, mU ml^−1^                 17.8 ± 6.8 (5.2--32.3)     25.5 (10.4--52.2)          0.002
  Ejection fraction, %           58.4 ± 2.8 (42--65)        57.5 (40--67)              NS

Values are mean ± SD (range). LDL = Low-density lipoprotein; NS = nonsignificant (p \> 0.10).
